IO Biotech’s Phase 3 trial showed Cylembio plus Keytruda improved progression-free survival in advanced melanoma across most subgroups.
IO Biotech’s Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This Year
Where Today's News Shapes Tomorrow
